Rallybio (RLYB) Operating Income (2020 - 2026)
Rallybio (RLYB) posted Operating Income of -$8.7 million for Q1 2026, down 36.2% sequentially from -$6.4 million in Q4 2025, and up 9.69% YoY from -$8.0 million in Q1 2025.
Rallybio (RLYB) Operating Income (2020 - 2026) Analysis & Trends
Rallybio has reported Operating Income for 7 years, with the latest figure at -$8.7 million in Q1 2026.
- Quarterly Operating Income rose 9.69% year-over-year to -$8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$32.1 million (up 36.23% YoY) and the FY2025 annual result came in at -$33.1 million, up 45.35% from the prior year.
- Operating Income eased to -$8.7 million in Q1 2026 per RLYB's latest filing, from -$6.4 million in the prior quarter.
- Over five years, Operating Income peaked at -$6.4 million in Q4 2025 and troughed at -$21.1 million in Q4 2023.
- A 5-year average of -$14.7 million and a median of -$17.0 million in 2024 frame the typical range for Operating Income.
- The sharpest annual moves came in 2022 and 2025: Operating Income tumbled 88.96% in 2022, then jumped 51.13% in 2025.
- Over 5 years, Operating Income stood at -$17.1 million in 2022, then retreated by 23.53% to -$21.1 million in 2023, then surged by 45.02% to -$11.6 million in 2024, then jumped by 44.76% to -$6.4 million in 2025, then plunged by 36.2% to -$8.7 million in 2026.
- According to Business Quant data, Operating Income over the past three periods registered -$8.7 million, -$6.4 million, and -$6.9 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 231.44 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -375.75 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -1.55 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 133.12 Mn |
| 10 | Rallybio | 94.61 Mn | 94.61 Mn | - | -5.65 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.65 Mn |
| Mar 31, 2026 | -8.73 Mn |
| Dec 31, 2025 | -6.41 Mn |
| Sep 30, 2025 | -6.93 Mn |
| Jun 30, 2025 | -10.06 Mn |
| Mar 31, 2025 | -9.67 Mn |
| Dec 31, 2024 | -11.61 Mn |
| Sep 30, 2024 | -12.07 Mn |
| Jun 30, 2024 | -17.04 Mn |
| Mar 31, 2024 | -19.79 Mn |
| Dec 31, 2023 | -21.11 Mn |
| Sep 30, 2023 | -19.36 Mn |
| Jun 30, 2023 | -20.08 Mn |
| Mar 31, 2023 | -18.37 Mn |
| Dec 31, 2022 | -17.09 Mn |
| Sep 30, 2022 | -18.86 Mn |
| Jun 30, 2022 | -17.62 Mn |
| Mar 31, 2022 | -14.32 Mn |
| Dec 31, 2021 | -12.31 Mn |
| Sep 30, 2021 | -9.98 Mn |